CSIR‑CCMB Researchers Identify DZIP3 as a Vital Viral Sensor

In a discovery that feels a bit like finding a hidden alarm system inside our own cells, a team of researchers at the CSIR‑Centre for Cellular and Molecular Biology (CCMB) in Hyderabad has pinpointed a protein called DZIP3 as a key player in the body’s early defence against viruses.

Led by Dr. Santosh Chauhan, the scientists published their findings in The EMBO Journal. The work shows that DZIP3 lies dormant inside a cell until it encounters viral RNA – the genetic script that viruses drop in when they hijack a host. Once it sniffs out this foreign material, DZIP3 undergoes a shape‑shift, becomes active and makes a beeline for the mitochondria, the cell’s little power stations.

It’s there, in the mitochondrial hub, that DZIP3 pulls the trigger for a cascade of events, ultimately prompting the production of type I interferons – the body’s own “stop‑the‑spread” signals. Those interferons act like emergency broadcasts, warning neighbouring cells and rallying the immune army to halt viral replication.

The team’s experiments revealed that this pathway isn’t a one‑trick pony. It offered protection against a diverse set of viruses, from the dreaded SARS‑CoV‑2 that caused the recent pandemic, to the mosquito‑borne Chikungunya and Japanese Encephalitis viruses. In each case, cells armed with a functional DZIP3 were far better at curbing the infection.

What makes this discovery especially satisfying is that it validates a hypothesis the Chauhan lab floated almost seven years ago – that certain human proteins could double‑duty as both viral sensors and rapid immune activators. The new data not only confirm that idea but also suggest that boosting DZIP3 activity, or mimicking its action, could become a strategy for designing broad‑spectrum antivirals.

“Understanding exactly how DZIP3 spots viral RNA and flips the switch on the cell’s defence machinery gives us a fresh perspective on innate immunity,” said Dr. Chauhan, Senior Principal Scientist at CCMB. “It’s a step toward therapies that aren’t limited to a single virus but can tackle many at once.”

While the road from lab bench to bedside is still long, the findings inject fresh optimism into the fight against emerging viral threats, especially in a world still reeling from recent pandemics.